ROBERT ALAN HROMAS, MD
Osteopathic Medicine in Gainesville, FL
License number
Florida 2003-0144
Category
Osteopathic Medicine
Type
Internal Medicine
License number
Florida ME109770
Category
Osteopathic Medicine
Type
Hematology
Address
Address
2
1600 Lomas Blvd. NE, Gainesville, FL 32610
918025 Msc10 5550, Orlando, FL 32891
918025 Msc10 5550, Orlando, FL 32891
Phone
(352) 273-7832
(352) 392-8530 (Fax)
(352) 392-8530 (Fax)
Personal information
See more information about ROBERT ALAN HROMAS at radaris.comName
Address
Phone
4626 SW 97Th Ter, Gainesville, FL 32608
4626 97Th St, Gainesville, FL 32608
4626 SW 97Th Ter, Gainesville, FL 32608
Professional information
Dr. Robert A Hromas, Gainesville FL - MD (Doctor of Medicine)
Address:
Hematology And Oncology
1600 SW Archer Rd SUITE N4, Gainesville 32610
(352) 273-7832 (Phone)
1600 SW Archer Rd SUITE N4, Gainesville 32610
(352) 273-7832 (Phone)
Hospitals:
Hematology And Oncology
1600 SW Archer Rd SUITE N4, Gainesville 32610
Shands Hospital at the University of Florida
1600 West Archer Rd, Gainesville 32608
1600 SW Archer Rd SUITE N4, Gainesville 32610
Shands Hospital at the University of Florida
1600 West Archer Rd, Gainesville 32608
Education:
Medical Schools
University Of Texas Medical School At Houston
Graduated: 1984
University Of Texas Medical School At Houston
Graduated: 1984
Robert A Hromas, Albuquerque NM
Specialties:
Internal Medicine, Hematology, Hematology & Oncology, Medical Genetics
Work:
University of New Mexico Hospital
2211 Lomas Blvd NE, Albuquerque, NM 87106 University of Florida
1600 Sw Archer Rd, Gainesville, FL 32610 Hematology/Oncology 111
2000 SW Archer Rd, Gainesville, FL 32608 Cancer Research & Treatment Center
715 Dr Martin Luther King Jr Ave NE, Albuquerque, NM 87102 Cancer Research & Treatment Center
900 Camino De Salud Ne, Albuquerque, NM 87131
2211 Lomas Blvd NE, Albuquerque, NM 87106 University of Florida
1600 Sw Archer Rd, Gainesville, FL 32610 Hematology/Oncology 111
2000 SW Archer Rd, Gainesville, FL 32608 Cancer Research & Treatment Center
715 Dr Martin Luther King Jr Ave NE, Albuquerque, NM 87102 Cancer Research & Treatment Center
900 Camino De Salud Ne, Albuquerque, NM 87131
Education:
The University of Texas at Houston (1984)
Novel Bifunctional Metnase/Intnase Inhibitors And Related Compositions And Methods Of Treatment Of Cancer
US Patent:
2012030, Nov 29, 2012
Filed:
Jan 26, 2011
Appl. No.:
13/574941
Inventors:
Robert Hromas - Gainesville FL, US
Andrei Leitao - Sao Carlos, BR
Tudor I. Oprea - Albuquerque NM, US
Larry A. Sklar - Albuquerque NM, US
Elizabeth A. Williamson - Gainesville FL, US
Justin Wray - Albuquerque NM, US
Wei Wang - Albuquerque NM, US
Andrei Leitao - Sao Carlos, BR
Tudor I. Oprea - Albuquerque NM, US
Larry A. Sklar - Albuquerque NM, US
Elizabeth A. Williamson - Gainesville FL, US
Justin Wray - Albuquerque NM, US
Wei Wang - Albuquerque NM, US
International Classification:
A61K 31/496, C07D 401/10, A61N 5/10, C07D 401/14, A61P 35/00, A61P 35/02, A61K 31/47, C07D 215/56
US Classification:
51425308, 514312, 544363, 546156, 600 1
Abstract:
This invention relates to novel cancer treatment compositions and associated therapeutic methods. More particularly, this invention relates in part to small chemical bifunctional inhibitors of DNA replication and repair proteins Metnase and/or Intnase (also termed Gypsy Integrase, Gypsy Integrease-1, Gypsy Retransposon Integrase 1, or GIN-I) that simultaneously damage DNA, and to a therapeutic method that utilizes the inhibitors to increase the effectiveness of cancer treatment protocols, including radiation therapy. In preferred embodiments, compounds, compositions and methods of treatment of the invention are used to treat a patient suffering from leukemia (e.g. acute myeloid leukemia (AML) and related cancers. In certain aspects of such treatments, compounds, compositions and methods of treatment of the invention are administered as a monotherapy (in some cases, to patients who have exhibited resistance to Topo IIalpha inhibitors such as VP-16), or are co-administered with a Topo IIalpha inhibitor or other anti-cancer agents as otherwise described herein or in combination with radiation therapy.